reason report
bottom line yesterday earn call increas
revenu forecast increas
earn forecast period increas
revenu forecast mainli due higher strensiq estim
higher along slightli increas soliri estim
us soliri sale trend posit driven primarili ex-u growth
us neurolog sale off-set patient convers ultomiri ultomiri
easili beat expect us ex-u expect
convers like met ahead schedul us
earli indic even rapid convers success earli
launch germani japan continu maintain posit
view compani stock expect alexion benefit
rapidli grow franchis also mid late stage
pipelin program well recent deal diversifi
compani pipelin addit clinic stage asset base
quarter result manag guidanc commentari
increas revenu forecast increas earn
estim base lower cog adjust revenu forecast
recent consensu thru adjust
ep estim consensu period
maintain outperform rate alexion stock price target
increas alexion stock benefit
continu growth exist product well increas investor
interest compani non-compl program approach
pivot trial key readout
averag dcf price-to-earnings
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target rate stock
outperform alexion lead compani develop commerci treatment
complement-medi diseas histor greater alexion revenu come
two rare diseas indic soliri recent approv soliri myasthenia
gravi nmo on-going launch ultomiri alexion final diversifi portfolio
beyond soliri two core ahu pnh indic believ alexion increas
revenu complement franchis competit threat soliri
overst view given long safeti efficaci histori soliri well alexion
progress develop improv version ultomiri greater potenc longer
half-lif conveni dose beyond complement kanuma strensiq continu
grow steadili still believ two product could combin contribut
expect oper margin maintain futur
find alexion well posit grow ep doubl digit next five year
complement franchis support neuro growth ultomiri convers
total sale soliri grow yoy growth
sequenti basi mix result across geographi soliri us sale
increas yoy driven continu growth neurolog franchis gener
myasthenia gravi gmg neuromyel optica spectrum disord nmosd sale appear
flat sequenti basi increas like due rapid pace ultomiri patient
convers manag indic total number gmg nmosd patient soliri
estim complic sequenti comparison prior quarter
includ gmg patient alexion expect neuro indic becom compani
largest franchis driven continu strength gmg adopt rate earli indic
robust demand nmosd eu sale yoy sequenti basi like
driven rapid ultomiri convers particularli germani convers
alreadi occur juli launch oct addit launch austria denmark
finland like continu slow trend eu manag continu guid
eu convers within year launch row sale yoy
sequenti driven primarili non-asia-pac region ask outlook soliri
transit manag suggest outlook residu soliri sale
face ultomiri convers would vari countri countri basi us
neuromuscular gmg nmo indic soliri like larg feasibl
soliri could gener flat compar pre-ultomiri revenu level market
neuro indic like materi soliri seem like erod rapidli
ultomiri introduct
alexion report ultomiri sale higher estim
consensu accord compani us pnh patient convert soliri
repres percentag point increas vs percentag point vs
demonstr consist slow growth penetr past two quarter expect
ultomiri reach compani convers goal first half origin
year end goal reassuringli compani explain rate convers
market ultomiri launch japan germani even faster
convers occur us manag expect greater quarterli fluctuat
ultomiri revenu given differ mainten vs induct dose price compar
soliri recent secur approv ahu us alexion continu see robust
convers soliri particularli given price save payer transit ahu
recent perman j-code also facilit reimburs coverag ultomiri oct
manag suggest recent japan launch track earli
progress us reimburs recent secur septemb ultomiri also
recent launch germani austria denmark finland provid addit
tailwind eu growth
metabol franchis put solid quarter doubl digit yoy growth report strensiq
kanuma driven primarili yoy volum growth strensiq
kanuma strensiq sale estim consensu
howev kanuma sale vs us line consensu alexion
continu identifi new patient current work facilit higher diagnosi
rate pediatr patient work improv ex-u fund agreement patient
ep beat driven top-lin growth
total non-gaap expens consensu
estim non-gaap expens
estim consensu sg came closer expect vs
consensu vs estim manag suggest would step
materi multipl pivot later-stag trial get underway alexion paid
tax rate averag dilut share count million quarter non-
basi report non- ep consensu estim
estim
alexion increas revenu non-gaap ep guidanc
compar guidanc
new revenu guidanc slightli higher consensu estim
updat non-gaap ep guidanc consensu
margin estim manag narrow non-gaap
expens guidanc compar guidanc soliris/ultomiri
guidanc estim consensu
total metabol revenu guidanc consensu expect
margin estim alexion expect expens
revenu sg expens slightli higher revenu give
oper margin non-gaap basi consensu oper margin
bracket estim margin new guidanc slightli
consensu estim midpoint estim
manag seem excit prospect expand pipelin includ
obtain thru recent transact stealth achillion achn/mp eido
eidx/op expand clinic stage pipelin asset potenti
new indic product launch could occur import
program probabl soon-to-b acquir achillion factor program along
phase wilson diseas program alexion manag suggest alexion
substanti financi capac pursu addit busi develop opportun
continu focu compani target rare diseas clinic stage asset
technolog platform potenti expand alexion capabl alexion
author addit share repurchas complet recent round
buyback approxim one year ahead previou author period buy-back
structur intend match compani current dilut employe stock option
issuanc stage compani seem inclin institut dividend materi
increas share repurchas activ
modest increas revenu forecast price
base recent quarter made chang revenu forecast valuat
assumpt increas price target total revenu forecast increas
thru mainli strensiq chang oper expens forecast
includ slightli lower oper expens thru follow subsequ
slightli higher oper expens thru mostli driven
decreas cog thru off-set increas sg
increas thru estim ebit higher
pro forma ep forecast higher thru compar consensu
updat revenu forecast higher higher higher
base chang updat price target maintain
outperform rate alexion stock next month alexion stock benefit
potenti decis co-develop elamipretid possibl ftc clearanc achillion
acquisit clariti prospect collabor caelum
bioscienc base final phase trial design
price target base simpl averag three
approach believ reason basi valu stock today approach
simpl price earn multipl compar large-cap biopharma compani
ratio discount cash flow dcf use rel multipl similar growth compani
ep appli ep estim alexion give fair valu
stock use expect ep compound-annual-growth-rate alexion period
current averag ratio larg molecul large-cap biotech give ep
multipl discount multipl compress alexion
appli ep estim give fair valu final dcf use termin
growth rate post give current valu averag three valuat
methodolog pt
risk view outlook valuat alexion includ major chang price
reimburs coverag label soliri compani main product today risk
includ commerci develop disappoint recent launch product strensiq
kanuma well develop disappoint addit indic soliri
successor complement inhibitor product final brand gener competitor
product soliri come market captur greater share caus greater market price
disrupt current expect futur outlook valuat would undermin
opportun better perform valu expect includ stronger initi
adopt recent launch new product forecast success develop
commerci new indic soliri beyond neuromyel optica
myasthenia gravi novel rare diseas medicin time horizon forecast
million
svb leerink llc research compani file
million
good sold
 total revenu
sg total revenu
svb leerink llc research compani file
brand
type event
event trial detail
date known
up/down
expect
combin waiha pv ph data
later
combin waiha pv ph data
later
biomark endpoint prelud larger pivot
annouc
option co-develop elamipretid could
close achn acquisit
sound like patient clinic poc studi
initi phase
bridg trial pnh indic
phase studi investig
add-on current standard-of-car therapi
svb leerink llc research compani file
analysi stock price svb leerink target alexion
multipl ep svb leerink estimate earn
current averag larg cap biopharma multipl ep
svb leerink adjust ep estim
capit
number period
impli target price
method leerink intrins valu base dcf current product net
current svb leerink dcf marketed/l stage program
current estim valu asset
method project forward earn multipl ep base ep
compound-annual-growth-rate larg cap biotech ratio
averag growth larg cap biotech co
impli ep multipl discount vs full growth-adj multipl
averag method
svb leerink llc research compani file factset
sale non-gaap
share count period dilut
guidanc
late stage pipelin program includ
late stage pipelin program exclud
